Aclarion Inc. (ACON), a commercial-stage healthcare company, announced on Tuesday that a second commercial agreement had been established with Weill Cornell Medicine, to conduct a study on lumbar surgery to treat degenerative disc disease, using the company's AI-driven platform Nociscan.
Nociscan combines artificial intelligence (AI) with magnetic resonance imaging (MRI) and was developed by Aclarion to non-invasively determine painful discs in the lumbar spine, to effectively treat chronic lower back pain (cLBP). cBLP effects about 266 million people worldwide, leading to degenerative disc disease (DDD). Nociscan identifies the location of disc pain by use of certain chemical biomarkers and has shown a 97% surgically verified success rate.
The two-year prospective, randomized study by Weill Cornell Medicine and Och Spine will be led by neurosurgeon Dr. Roger Hartl, and aims to increase knowledge on DDD, its natural history, causes, and potential treatment. Nociscan will be utilized to evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate (BMAC) injection on patient reported outcomes, intervertebral disc (IVD) health, and pain biomarkers.
Hartl was quoted, saying, "This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging".
ACON closed Monday at $3.31, down 3.22%. In the pre-market, the stock is trading at $3.24, down 2.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.